Autonomix Medical, Inc. announced the successful completion of an animal study evaluating the Company?s proprietary catheter-based sensing technology for use in the renal artery. The preclinical porcine model study was designed to assess the ability of the Company?s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery. For the study, epivascular injections of ethanol were given to target nerves and the Company?s sensing technology was successfully able to capture the down-regulated nerve signal of the treated nerve from within the renal artery, as well as the return to normal signal post ethanol treatment.

These results strongly demonstrate the potential of Autonomix?s sensing technology to successfully locate nerves around the renal artery. These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension. The Company?s catheter-based sensing technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment.

Autonomix believes this technology is a better alternative to the current approaches commonly used, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body. The Company is initially developing its technology to address pancreatic cancer-related pain. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.